Skip to main content
padlock icon - secure page this page is secure

Treatment of MEK inhibitor‐induced paronychia with doxycycline

Buy Article:

$52.00 + tax (Refund Policy)

A 12‐year‐old girl with neurofibromatosis type 1 and a large facial plexiform neurofibroma had been participating in a selumetinib clinical trial for the past 5¬†years. Despite decreased tumor size, she developed recalcitrant selumetinib‐induced paronychia. Various antibiotics, topical medications, and surgeries were only minimally effective. Full‐dose doxycycline resolved the paronychia, and sub‐antimicrobial dosing has prevented recurrences for several months, permitting her to continue her selumetinib course.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: MEK inhibitor; NF1; doxycycline; neurofibromatosis; paronychia; selumetinib

Document Type: Research Article

Publication date: September 1, 2020

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more